Formation of platinum-DNA adducts in pediatric patients receiving carboplatin

Margaret E. Tonda, Daryl J. Murry, John H. Rodman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Study Objective. To determine the extent of platinum-DNA (Pt-DNA) adduct formation in peripheral white blood cells of children with cancer. Design. Prospective study. Setting. Pediatric research hospital. Patients. Twenty- seven children receiving carboplatin as part of therapy as defined by clinical research protocols. Interventions. Patients received various dosages of carboplatin over 1, 3, or 24 hours as a primary component of combination chemotherapy for pediatric solid tumors, brain tumors, or large cell lymphoma. Measurements and Main Results. The Pt-DNA adducts were detectable in 10 (37%) of 27 patients. The median value was 3.4 fmol Pt/μg DNA (range 1.7-31.2 fmol) in patients with measurable values. Conclusion. The Pt-DNA adducts were detected less frequently in pediatric patients than reported in adults. Variables that influenced their detection were higher carboplatin dosages or systemic exposure and short (1-3 hrs) versus prolonged (24 hrs) infusions.

Original languageEnglish (US)
Pages (from-to)631-637
Number of pages7
JournalPharmacotherapy
Volume16
Issue number4
StatePublished - Jul 1 1996

Fingerprint

DNA Adducts
Carboplatin
Platinum
Pediatrics
Pediatric Hospitals
Clinical Protocols
Combination Drug Therapy
Brain Neoplasms
Lymphoma
Neoplasms
Leukocytes
Prospective Studies
DNA
Research

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Formation of platinum-DNA adducts in pediatric patients receiving carboplatin. / Tonda, Margaret E.; Murry, Daryl J.; Rodman, John H.

In: Pharmacotherapy, Vol. 16, No. 4, 01.07.1996, p. 631-637.

Research output: Contribution to journalArticle

Tonda, Margaret E. ; Murry, Daryl J. ; Rodman, John H. / Formation of platinum-DNA adducts in pediatric patients receiving carboplatin. In: Pharmacotherapy. 1996 ; Vol. 16, No. 4. pp. 631-637.
@article{acfaa0e8d3914fbd83cda8f48c0842ed,
title = "Formation of platinum-DNA adducts in pediatric patients receiving carboplatin",
abstract = "Study Objective. To determine the extent of platinum-DNA (Pt-DNA) adduct formation in peripheral white blood cells of children with cancer. Design. Prospective study. Setting. Pediatric research hospital. Patients. Twenty- seven children receiving carboplatin as part of therapy as defined by clinical research protocols. Interventions. Patients received various dosages of carboplatin over 1, 3, or 24 hours as a primary component of combination chemotherapy for pediatric solid tumors, brain tumors, or large cell lymphoma. Measurements and Main Results. The Pt-DNA adducts were detectable in 10 (37{\%}) of 27 patients. The median value was 3.4 fmol Pt/μg DNA (range 1.7-31.2 fmol) in patients with measurable values. Conclusion. The Pt-DNA adducts were detected less frequently in pediatric patients than reported in adults. Variables that influenced their detection were higher carboplatin dosages or systemic exposure and short (1-3 hrs) versus prolonged (24 hrs) infusions.",
author = "Tonda, {Margaret E.} and Murry, {Daryl J.} and Rodman, {John H.}",
year = "1996",
month = "7",
day = "1",
language = "English (US)",
volume = "16",
pages = "631--637",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Formation of platinum-DNA adducts in pediatric patients receiving carboplatin

AU - Tonda, Margaret E.

AU - Murry, Daryl J.

AU - Rodman, John H.

PY - 1996/7/1

Y1 - 1996/7/1

N2 - Study Objective. To determine the extent of platinum-DNA (Pt-DNA) adduct formation in peripheral white blood cells of children with cancer. Design. Prospective study. Setting. Pediatric research hospital. Patients. Twenty- seven children receiving carboplatin as part of therapy as defined by clinical research protocols. Interventions. Patients received various dosages of carboplatin over 1, 3, or 24 hours as a primary component of combination chemotherapy for pediatric solid tumors, brain tumors, or large cell lymphoma. Measurements and Main Results. The Pt-DNA adducts were detectable in 10 (37%) of 27 patients. The median value was 3.4 fmol Pt/μg DNA (range 1.7-31.2 fmol) in patients with measurable values. Conclusion. The Pt-DNA adducts were detected less frequently in pediatric patients than reported in adults. Variables that influenced their detection were higher carboplatin dosages or systemic exposure and short (1-3 hrs) versus prolonged (24 hrs) infusions.

AB - Study Objective. To determine the extent of platinum-DNA (Pt-DNA) adduct formation in peripheral white blood cells of children with cancer. Design. Prospective study. Setting. Pediatric research hospital. Patients. Twenty- seven children receiving carboplatin as part of therapy as defined by clinical research protocols. Interventions. Patients received various dosages of carboplatin over 1, 3, or 24 hours as a primary component of combination chemotherapy for pediatric solid tumors, brain tumors, or large cell lymphoma. Measurements and Main Results. The Pt-DNA adducts were detectable in 10 (37%) of 27 patients. The median value was 3.4 fmol Pt/μg DNA (range 1.7-31.2 fmol) in patients with measurable values. Conclusion. The Pt-DNA adducts were detected less frequently in pediatric patients than reported in adults. Variables that influenced their detection were higher carboplatin dosages or systemic exposure and short (1-3 hrs) versus prolonged (24 hrs) infusions.

UR - http://www.scopus.com/inward/record.url?scp=0029835814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029835814&partnerID=8YFLogxK

M3 - Article

C2 - 8840369

AN - SCOPUS:0029835814

VL - 16

SP - 631

EP - 637

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 4

ER -